+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Health News Eli Lilly S Swiss Lab Closure Worries Animal Rights Group is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Health News Eli Lilly S Swiss Lab Closure Worries Animal Rights Group | RobinsPost News & Noticias



Why the FDA rejected Eli Lilly's attempt for quick approval of Alzheimer's drug


The Food and Drug Administration rejected Eli ... Alzheimer's drug donanemab. Despite the setback, Lilly expects to report results by mid-year on a large, late stage study of the drug. The ... Read More

Eli Lilly's Alzheimer's drug hits a regulatory hurdle. But our belief in the stock isn't shaken


Eli Lilly 's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. While the setback hit the stock Friday, it's not rattling our long-term ... Read More

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead


Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by ... Read More



Eli Lilly Had a Strong Year in 2022. It's Expecting an Even Better 2023.


Eli Lilly expects 2022 profits to rise by only single digits. But this year the company is expecting far more impressive results. Earnings per share could increase by up to 18%. Last month, Eli ... Read More

Who Was The Real Eli Lilly?


Today, there is a museum dedicated to Lilly's Civil War service, which is located in Indianapolis (via Museums of the World). Even before Eli Lilly ... medicines and animal medicine, as well ... Read More

Eli Lilly's Alzheimer’s Drug Donanemab Fails to Get Early FDA Approval


Eli Lilly & Co.’s bid for accelerated approval of its Alzheimer’s therapy donanemab was rejected by U.S. regulators, an unexpected setback for the drugmaker. The Food and Drug Administration ... Read More

Eli Lilly And Company (LLY): Today's Featured Health Care Winner


Eli Lilly and Company was a winner within the health care sector, rising 31 cents (0.7%) to $42.07 on light volume. Eli Lilly and Company was a winner within the health care sector, rising 31 ... Read More

Lilly partners with Sidekick in digital health alliance


A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge ... specialist Sidekick and pharma group Eli Lilly. The two companies say the ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus